October 9, 2020 7:37pm

Monday, bond markets are closed but, the equity market remain open on Columbus Day

Pre-open indication results: 6 HITs and 0 MISS

Week in review …

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't.

Subscription is coming, my gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

The Dow closed UP +164.39 points (+0.57%), the S&P closed UP +30.30 points (+0.88%) while the Nasdaq closed UP +148.96points (+1.39%)

 

Henry’omics:

Indexes rose on Friday to end their best week in months as President Trump signaled support for a bigger coronavirus aid package.

  • The administration has raised its offer for a new aid package to $1.8 trillion from $1.6 trillion.

Intellia Therapeutics (NTLA +14.69%) and Fate therapeutics (FATE +6.74%) led their RegMed, cell and gene therapy sector higher while the laggards included Sage Therapeutics (SAGE -$4.62%) and Homology Medicine (FIXX -4.31%).

 

This morning, I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: expectation is surrounded by skepticism … https://www.regmedinvestors.com/articles/11582

 

Pre-open indications: 6 HITs < Biostage (BSTG -$0.00), BUY: Precigen (PGEN +$1.19); SELL into Strength - Sage Therapeutics (SAGE -$3.60), CRISPR Therapeutics (CRSP +$2.87), Intellia Therapeutics (NTLA +$3.37), Fate Therapeutics (FATE +$3.03) – always good to profit and 0 MISS

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Friday opened positive at 19/13 and 3 flats, stayed positive at the mid-day at 25/8 and 2 flats, closing positive at 21/9 and 5 flats;
  • Thursday opened positive at 21/13 and 1 flat, strayed negative at the mid-day at 16/18 and 1 flat, closing positive at 18/14 and 3 flats;
  • Wednesday opened positive at 27/6 and 2 flats, stayed positive at the mid-day at 28/5 and 2 flats, closing positive at 26/7 and 2 flats;
  • Tuesday opened positive at 17/15 and 2 flats, stayed positive at the mid-day at 21/13 and 1 flat, closing negative at 11/23 and 1 flat;
  • Monday opened positive at 31/3 and 1 flat, stayed positive at the mid-day at 33/1 and 1 flat, closing positive at 33/1 and 1 flat;

 

Key metrics:

  • Sector volume was the usual LOW with 7 of the 21-upside having higher than the 3-month average volume with the increased volume of 2 of 9-downside having higher than the 3-month average volume;
  • Friday’s percentage (%) of the 21-upside were +0.02% (RARE) to +29.02% (PGEN) while the 9-downside ranges from -0.23% (BLUE) to -4.62% (SAGE);

 

Hammered in today’s market:

  • ReNeuron (RENE.L), Sage Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Homology Medicine (FIXX), uniQure NV (QURE) to name 5 of the 9 declining of the 35 covered

Jumping with share pricing momentum:

  • Intellia Therapeutics (NTLA), Fate Therapeutics (FATE), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Precigen (PGEN) to name 5 of the 21 inclining of the 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed up +0.81% and XBI closed up +0.92%
  • Thursday, the IBB closed up +0.28% and XBI closed up +0.45%
  • Wednesday, the IBB closed up +2.26% and XBI closed up +3.20%
  • Tuesday, the IBB closed down -1.21% and XBI closed down -0.79%
  • Monday, the IBB closed up +4.26% and XBI closed up +4.94%

 

Friday’s (10 of 21) incliners:

  • Intellia Therapeutics (NTLA +$3.37 after Thursday’s -$0.84, Wednesday’s +$2.77, Tuesday’s +$0.24 and Monday’s +$1.94);
  • Fate Therapeutics (FATE +$3.03 after Thursday’s +$0.94, Wednesday’s +$2.48, Tuesday’s -$0.33 and Monday’s +$3.80),
  • CRISPR Therapeutics (CRSP +$2.87 after Thursday’s -$2.29, Wednesday’s +$9.96, Tuesday’s +$0.97 and Monday’s +$7.08);
  • Editas Medicine (EDIT +$2.38 after Thursday’s -$0.29, Wednesday’s +$2.28, Tuesday’s -$0.38 and Monday’s +$2.07);
  • Precigen (PGEN +$1.28);
  • Alnylam Pharmaceuticals (ALNY +$0.96 after Thursday’s +$0.64, Wednesday’s +$2.14, Tuesday’s +$1.26 and Monday’s+$6.32),
  • Sangamo Therapeutics (SGMO +$0.94 after Thursday’s -$0.36);
  • AxoGen (AXGN +$0.830;
  • Global Blood Therapeutics (GBT +$0.81 after Thursday’s -$2.22 after Wednesday’s +$1.96, Tuesday’s +$0.02 and Monday’s +$4.79);
  • Cellectis SA (CLLS +$0.68 after Thursday’s +$0.95);

Friday’s (9 of 9) decliner:

  • ReNeuron (RENE.L -$3.60 after Thursday’s -$0.90);
  • Sage Therapeutics (SAGE -$3.12 after Thursday’s +$1.99, Wednesday’s +$1.42 and Tuesday’s +3.97);
  • Ionis Pharmaceuticals (IONS -$0.92 after Thursday’s +$0.42, Wednesday’s +$1.12 and Tuesday’s -$2.28);
  • Homology Medicine (FIXX -$0.49);
  • uniQure NV (QURE -$0.37 after Thursday’s -$0.37) and Wednesday’s -$0.14);
  • Voyager therapeutics (VYGR -$0.32 after Thursday’s +$0.48);
  • Brainstorm Cell Therapeutics (BCLI -$0.18 after Thursday’s +$0.72);
  • bluebird bio (BLUE -$0.13 after Thursday’s -$0.00 after Wednesday’s +$1.66);
  • Solid Bioscience (SLDB -$0.01 after Thursday’s -$0.06, Wednesday’s -$0.27 and Tuesday’s -$0.38);

Closing flat –5 – Biostage (BSTG), Mesoblast (MESO), Athersys (ATHX), Caladrius biosciences (CLBS) and Stemline Therapeutics (STML – acquired)

 

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

  • Friday’s percentage (%) of the 21-upside were +0.02% (RARE) to +29.02% (PGEN) while the 9-downside ranges from -0.23% (BLUE) to -4.62% (SAGE);
  • Thursday’s percentage (%) of the 18-upside were +0.17% (MESO) to +7.09% (BLCM) while the 14-downside ranges from -0.16% (AXGN) to -3.53% (NTLA);
  • Wednesday’s percentage (%) of the 26-upside were +0.54% (CLBS) to +13.18% (NTLA) while the 9-downside ranges from -0.31% (BLFS) to -6.18% (SLDB);
  • Tuesday’s percentage (%) of the 11-upside were +0.03% (GBT) to +6.60% (SAGE) while the 23-downside of -0.07% (BLUE) to -8% (SLDB);
  • Monday’s percentage (%) of the 33-upside were +0.52% (RENE.L) to +13.64% (SLDB) while the 1-downside of -0.30% (MDXG);

 

Sentiment and a few daily indicators:

The White House plans to increase its coronavirus relief offer to $1.8 trillion as it scrambles to craft a relief deal with Democrats.

  • The sides have struggled to find a compromise between the Trump administration’s last $1.6 trillion proposal and the $2.2 trillion bill House Democrats passed earlier this month. Outstanding disputes include state and local government relief, unemployment insurance, tax credits and liability protections for businesses and schools. <CNBC>

Infection cases <Million>:

  • Friday 7.6 M cases
  • Thursday 7.55 M cases
  • Wednesday 7.5 M cases
  • Tuesday 7.45 M cases
  • Monday 7.44 M cases

Friday’s death rate totaled 212,789 after Thursday’s 211,844, Wednesday’s 210,918, Tuesday’s 210,195, Monday’s 210.013 and last Friday’s 207,818 a <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Friday: 7 out of the 21-upside had higher than the 3-month average volume;
  • Thursday: 5 out of the 18-upside had higher than the 3-month average volume;
  • Wednesday: 8 out of the 26-upside had higher than the 3-month average volume;
  • Tuesday: 3 out of the 11-upside had higher than the 3-month average volume;
  • Monday: 12 out of the 33-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -1.36 points or -5.16% at 25.00
  • Thursday was down -1.66 points or -5.92% at 26.40
  • Wednesday was down -1.42 points or -4.82% at 28.06
  • Tuesday was up +0.10 points or +0.36% at 28.06
  • Monday was up +0.33 points or +1.19% at 27.96

Downside volume:

  • Friday: 2 out of the 9-downside had higher than the 3-month average volume;
  • Thursday: 5 out of the 14-downside had higher than the 3-month average volume;
  • Wednesday: 0 out of the 9-downside had higher than the 3-month average volume;
  • Tuesday: 4 out of the 23-downside had higher than the 3-month average volume;
  • Monday: 1 out of the 1-downside had higher than the 3-month average volume;

 

October, the first month <October> of Q4 …

Friday closed positive with 21 advancers, 9 decliners and 5 flats 

Thursday closed positive with 18 advancers, 14 decliners and 3 flats

Wednesday closed positive with 26 advancers, 9 decliners and 2 flats 

Tuesday closed negative with 11 advancers, 23 decliners and 1 flat 

Monday (10/5) closed positive with 33 advancers, 1 declined and 1 flat 

Friday closed negative with 8 advancers, 26 decliners and 1 flat 

Thursday (10/1) closed negative with 21 advancers, 12 decliners and 2 flats

 

The Bottom Line: I’d rather be a flat than a splat. As I stated yesterday and the day before, “profit now, a market storm is brewing”.

Q3 earnings LPS (loss-per-share) results are being prepared. Not bad at all, a better week was had 4 up sessions out of 5, the advance/decline (A/D) lines were in good form; the IBB and XBI manifested positivity and to top it all – my prognostications were i.e. pre-open indications were right again … it’s getting to be a constant!

Yet, I am wary of what and how October will play into November for “our’ universe!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.